With Consumer Genetic Testing, Buyer Beware
By Editorial,
The Boston Globe
| 09. 30. 2014
Untitled Document
THE ERA OF direct-to-consumer genetic testing means that anyone can pay $99, spit into a plastic vial, and get back a detailed readout on ancestry and risk factors for scores of diseases. At the forefront of this wave is Silicon Valley startup 23andMe, which has collected the DNA of 700,000 members since it was founded in 2006. This flood of data, however, raises a host of ethical questions that neither testing firms nor their customers may anticipate — especially when unwanted information invades customers’ lives.
The Food and Drug Administration moved last year to protect DNA testing consumers from being bombarded with alarming warnings and hard-to-interpret risk assessments about their health that might give rise to unnecessary procedures. Still, the company can provide consumers with the raw data, allowing them to find experts to interpret it for them. That’s a fair compromise: Americans should be able to obtain information about their genetic background; testing firms should be able to present that information with a minimum of hype.
Another source of controversy is 23andMe’s growing genetic database. As...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
